ProQR's AX-0810 Shows Promising Phase 1 Data for Cholestatic Liver Diseases — ProQR Therapeutics N.V.

Event summary

ProQR's AX-0810 demonstrated dose-dependent target engagement in Phase 1 study, with up to 8-fold change in total bile acids in serum.
No serious adverse events or pruritus reported, with a favorable safety and tolerability profile observed.
AX-0810 showed a half-life of eight weeks, supporting sustained target engagement.
ProQR plans to advance AX-0811, a next-generation NTCP EON, with CTA filing expected in mid-2026.

The big picture

ProQR's positive Phase 1 data for AX-0810 validates its Axiomer RNA editing platform, positioning the company as a key player in the development of transformative RNA therapies. The favorable safety profile and target engagement results strengthen ProQR's pipeline potential, particularly in addressing cholestatic liver diseases with significant unmet medical needs.

What we're watching

Clinical Validation: How the Phase 1 data for AX-0810 will influence the design and timing of future clinical studies in biliary atresia.
Pipeline Progression: Whether AX-0811 can deliver on its projected benefits, including higher editing efficiency and longer half-life.
Regulatory Pathway: The pace at which ProQR can secure regulatory approvals for AX-0810 or AX-0811 in biliary atresia.